Sun Pharma Surges Over 6% on New Drug Approval

Sun Pharma shares surged over 6 per cent on Friday after it said that one of its subsidiary has bagged the final approval from US drug regulator (USFDA) for abbreviated new drug application (ANDA) for generic version of Gleevec, Imatinib Mesylate tablets 100 mg and 400mg.  Imatinib Mesylate tablets, 100 mg and 400 mg are therapeutic equivalents of Novartis' Gleevec, which has annual sales of $2.5 billion in the US, Sun Pharma said i...